Login to Your Account



Intra-Cellular Signs Potential $750M+ Schizophrenia Deal

By Tom Wall


Friday, March 4, 2011
Since it was founded in 2003 by a group that included 2000 Nobel Prize winner Paul Greengard, privately held Intra-Cellular Therapies Inc. has focused on developing drugs for central nervous system disorders like schizophrenia, Alzheimer's disease and Parkinson's disease. Seldom seeking attention from the press, the company generally flew under the biotech industry radar.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription